ZimVie (NASDAQ:ZIMV) Issues FY 2025 Earnings Guidance

ZimVie (NASDAQ:ZIMV - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.800-0.950 for the period, compared to the consensus estimate of 0.750. The company issued revenue guidance of $445.0 million-$460.0 million, compared to the consensus revenue estimate of $458.0 million.

ZimVie Stock Up 3.0 %

ZIMV traded up $0.39 during trading hours on Friday, hitting $13.27. 112,015 shares of the company's stock were exchanged, compared to its average volume of 243,368. ZimVie has a 12-month low of $12.25 and a 12-month high of $22.40. The firm has a 50 day moving average of $13.75 and a 200 day moving average of $14.72. The firm has a market cap of $367.27 million, a P/E ratio of -1.01 and a beta of 2.10. The company has a current ratio of 1.94, a quick ratio of 1.38 and a debt-to-equity ratio of 0.57.

ZimVie (NASDAQ:ZIMV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.25 by $0.02. ZimVie had a negative net margin of 77.31% and a positive return on equity of 2.90%. The company had revenue of $111.52 million during the quarter, compared to analysts' expectations of $113.67 million. Analysts predict that ZimVie will post 0.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a "buy" rating and issued a $23.00 target price on shares of ZimVie in a report on Thursday.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.